Dozens of Retractions Requested for Heart Stem Cell Studies

Harvard and Brigham and Women’s Hospital disavow the work by former faculty member Piero Anversa.

Written byAshley P. Taylor
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, RAZVAN25

Harvard Medical School and Brigham and Women’s Hospital announced yesterday (October 14) that following an internal investigation they recommend the retraction of 31 papers by a former faculty member, cardiac stem cell researcher Piero Anversa, as Retraction Watch and STAT report. These studies “included falsified and/or fabricated data,” the two institutions tell Retraction Watch and STAT, adding that they have “notified all relevant journals.”

This is the latest in a series of black marks on research by Anversa, who claimed, as early as 2003, to have identified adult stem cells—dubbed c-kit cells—that can regenerate cardiac muscle. Efforts by other labs to reproduce Anversa’s findings and to use the cells to heal damaged hearts have produced contradictory and sometimes mysterious results.

In 2014, Anversa and coauthors had a paper retracted from the journal Circulation after Harvard Medical School and Brigham and Women’s determined that data were “compromised,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies